Finanzen von ADICET Bio, Inc. (ACET)ACETADICET Bio, Inc.

Evaluating the bottom line, ADICET Bio, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -85.91%, provide a clear picture of how effectively ACET converts its operational activities into shareholder value.

In the context of the broader market, ACET competes directly with industry leaders such as PPBT and COSM. With a market capitalization of $28.27M, it holds a significant position in the sector. When comparing efficiency, ACET's gross margin of N/A stands against PPBT's N/A and COSM's 6.12%. Such benchmarking helps identify whether ADICET Bio, Inc. is trading at a premium or discount relative to its financial performance.

Adicet Bio has been experiencing substantial losses, with a net income loss of $21.36 million in Q2 2026 and a gross profit of $0.00 in Q4 2024, indicating significant financial challenges. The company's forward P/E ratio is 0, reflecting a lack of earnings expectations in the near term.